


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (canceled)

Claim 2. (currently amended) A compound of the formula



wherein R_1 is independently selected from the group consisting of H; alkyl; substituted alkyl; alkoxy; halo; substituted alkoxy; hydroxy; trifluoralkyl; nitro; amino; alkylamino; cycloalkylamino; cyano; carboxy; cycloalkyl; phenyl; and substituted phenyl;


R_2 is independently selected from the group consisting of H; alkyl; substituted alkyl; halo; heterocycloalkyl; heteroaryl; phenyl; substituted phenyl; naphthyl and substituted naphthyl;

B_1 is hydrogen;


B_2 is hydrogen; or B_1 and B_2 are methylene and joined together to form a five or six membered ring;

Y is methylene or carbonyl;


- L is selected from the group consisting of
C₁₋₈alkylene; C₂₋₁₀alkenylene; C₂₋₁₀alkynylene; C₃₋₇cycloalkylene;
C₃₋₇cycloalkylC₁₋₄alkylene;
arylC₁₋₄alkylene;
 α -aminoC₄₋₇alkylene;




- (N-methylene)piperidin-4-yl;




- (N-methylene)piperazin-4-yl;




- (N-methylene)pyrrolidin-3-yl;



- (N-methylene)-4-acetyl-piperidin-4-yl;




and (N-methylene)piperidin-4,4-diyl;




Z is selected from the group consisting of


aryl;




N-sulfonamido;




N-(aryl)sulfonamido;




arylamido;




arylureido;




arylacetamido:




(aryloxy)carbonylamino;



2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;



and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;



R_3 is independently selected from the group consisting of C_{1-6} alkyl; substituted C_{1-6} alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl; and substituted heteroaryl;

R_4 is independently selected from the group consisting of hydrogen;

C₁₋₈alkyl; C₁₋₈alkoxy; substituted C₁₋₈alkoxy; hydroxy; halogen; cyano; nitro; amino; C₁₋₈alkylamino; and C₁₋₈dialkylamino;

R₅ is independently selected from the group consisting of hydrogen; C₁₋₈alkyl; C₁₋₈alkylcarbonyl; aroyl; carbamoyl; amidino; C₁₋₈alkyl; C₁₋₈alkylaminocarbonyl; (aryl amino)carbonyl; and arylC₁₋₈ alkylcarbonyl;

R₆ is independently selected from hydrogen and C₁₋₈alkyl;

n is 1-2;

m is 0-3;


p is 1-3; and

q is 1-3;

provided that when Z is aryl or heteroaryl, L is (N-methylene)piperazin-4-yl or (N-methylene)-4-acetylpiperidin-4-yl; provided that when L is (N-methylene)piperazin-4-yl, Z is phenyl or naphthyl; when L is (N-methylene)-4-acetylpiperidin-4-yl, Z is phenyl or naphthyl and Y is carbonyl; and when Z is N-sulfonamido or N-(aryl)sulfonamido, L is α -aminoC₄₋₇alkylene, (N-methylene)piperidin-4-yl or (N-methylene)pyrrolidin-3-yl;







and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 3. (previously presented) A compound of claim 2 selected from the group consisting of:




and

Claim 4. (previously presented) A compound of claim 2 selected from the group consisting of:



and

Claim 5. (previously presented) A compound of claim 2 selected from the group consisting of:




and

Docket No. ORT-1588
Serial No. 10/071,483

Claim 6. (canceled)






Claim 7. (canceled)

Claim 8. (previously presented) A compound of claim 2 selected from the group consisting of:



and

Claim 9. (previously presented) A compound of claim 2 selected from the group consisting of:




and

Docket No. ORT-1588
Serial No. 10/071,483

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (previously presented) A compound of claim 2 selected from the group consisting of:



and

Claim 13. (canceled)

Claim 14. (canceled)

Claim 15. (canceled)

Claim 16. (canceled)

Claim 17. (previously presented) A method of treating disorders and diseases associated with NPY receptor subtype 5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.

Claim 18. (previously presented) A pharmaceutical composition for the treatment of diseases or disorders associated with the NPY Y5 receptor subtype comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.

Claim 19. (currently amended) A pharmaceutical composition according to claim 18 for the treatment of disorders or disease states caused by eating disorders, obesity, ~~bulimia nervosa~~, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression and anxiety.